Purpose of review The aim is to review recent findings on immunity and vaccine development to Chlamydia trachomatis.
Introduction
Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium. Serovars A-C cause trachoma, D-K cause the common sexually transmitted infection (STI) and L1-L2 cause lymphogranuloma venereum [1] . This review focuses on immunity and vaccination against the common STI.
Prevalence of C. trachomatis STI in Europe is 1-3% of the population between the ages of 18 and 44. Reinfection is common and most cases are asymptomatic [2] . It is accepted that C. trachomatis STI in some women leads to pelvic inflammatory disease (PID), tubal infertility and ectopic pregnancy although the evidence remains associative. There is also pathology associated with genital infection in men [3, 4] .
The host response to infection: immunity and disease following Chlamydia trachomatis sexually transmitted infection Because widespread antibiotic therapy was introduced, serum anti-C. trachomatis antibodies have declined in parallel with increased C. trachomatis prevalence [5, 6] . Whilst clearing infection, antibiotics may alter the development of immunity. It remains controversial whether pathology is caused directly by infection or by the immune response. There is evidence that women who make a pro-inflammatory, interferon-g (IFN-g)-dominated cytokine response (T helper type 1 or Th1 response) have less re-infection and infertility than those who make IL-10 and IL-4 dominated Th2 responses [7 ,8 ] . As IFN-g induces a persistent noninfectious state in C. trachomatis in vitro [9 ,10], it remains unclear whether a Th1 response completely clears infection in vivo. Th1 dependent IgG2 antibodies to C. trachomatis antigens are higher in women with cervicitis and PID [11 ] , indicating that Th1 responses may be associated with inflammatory pathology.
The potential solution: is a vaccine likely to be beneficial?
Modelling indicates that fully protective vaccination would eliminate C. trachomatis epidemics in 20 years. A partially effective vaccine would reduce disease in men and women, but cost-benefit would be greater for vaccinating women only [12 ] . To develop vaccines it is necessary to understand how C. trachomatis gains entry to and survives inside host cells; which bacterial proteins induce immune responses; and which immune responses are protective.
Protective immunity generated by vaccination should not be confused with the immune response to STI. This is due to the context in which C. trachomatis antigens are seen by the immune system. In vaccination this is determined by the adjuvant(s) used and the route of administration. In natural infection C. trachomatis has evolved mechanisms to ensure that immune responses are suboptimal and/or are directed at proteins which are not essential for transmission or re-infection.
Complexity in miniature: the Chlamydia trachomatis lifecycle
The C. trachomatis chromosome encodes nearly 1000 proteins. Most isolates have a plasmid encoding eight or nine proteins which influence bacterial gene transcription [13] . C. trachomatis has a bimorphic lifecycle. The metabolically inactive, infectious, elementary bodies have an extensively crosslinked outer membrane which makes them very stable extracellularly. The main structural components are the major outer membrane protein (MOMP/OmpA), OmcA and OmcB. Other proteins are involved in tropism and attachment. Heinz et al. [14 ] used an in-silico approach and Liu et al. [15 ] used proteomics to identify several outer membrane proteins which may be targets for intervention strategies. Manipulating the environment: pathogeninduced host cell changes C. trachomatis can use the cystic fibrosis transmembrane conductance regulator (CFTR) membrane protein to enter cells [17 ] . CFTR upregulation is associated with C. trachomatis-induced female infertility [18 ] . Elementary body entry depends on host membrane protein disulfide isomerase (PDI) [19 ] , which targets crosslinked elementary body outer membrane proteins. PDI is a component of the estrogen receptor alpha (ERa) complex which associates with C. trachomatis attached to human endometrial epithelial cells [20] . Interaction with the ERa complex may be a target for prevention of infection as the coreceptor protein SRAP-1 is targeted by a C. trachomatis protease (CT441) to inhibit ERa signalling [21 ] .
Inside permissive cells, elementary bodies transition into
Inside host cells C. trachomatis circumvents endogenous stress mechanisms, prevents lysosomal fusion, inhibits apoptosis, and evades intracellular innate immunity. Cocchiaro and Valdivia [22 ] reviewed intracellular survival mechanisms and Betts et al. [23 ] reviewed how C. trachomatis effector proteins alter host cells. On entry, the elementary body protein TARP translocates into the cytoplasm, is phosphorylated by Src and remodels actin to allow the elementary body to move within the cell. The elementary body becomes surrounded by host cell membrane to form the inclusion body and C. trachomatis proteins are inserted into the inclusion body membrane. The inclusion body diverts and fuses with host cell vesicles containing nutrients necessary for replication. CPAF, a reticulate body protease secreted into the cytoplasm, degrades cytoskeletal elements to allow inclusion body expansion and release of elementary bodies, and processes intermediate-filament proteins to stabilize the inclusion bodies and minimize exposure to intracellular Immunity to genital Chlamydia trachomatis infection Howie et al. 57
Key points
Chlamydia trachomatis genital infection is associated with subsequent reproductive pathology and infertility. Infection with C. trachomatis induces partial immunity at best. Vaccination against C. trachomatis would significantly reduce disease burden and healthcare costs. Protective immunity can be induced experimentally. Human C. trachomatis vaccine candidates and adjuvants require further study.
innate immune mechanisms [24 ] . CPAF also degrades pro-apoptotic proteins [24 ] and TARP interacts with the host adaptor protein SHC1 to inhibit apoptosis [25 ] . Caspase-1 activation promotes C. trachomatis replication [26 ] . C. trachomatis disrupts several signalling pathways [27 ] . In epithelial cells RAS decouples from MAPK/ ERK (MEK) signalling although the effects differ in human and murine cells [28 ] . The C. trachomatis proteins ChlaDub1 and CT441 interfere with host cell NF-kB signalling [23 ] .
Fighting back: immune responses to Chlamydia trachomatis
Each C. trachomatis protein may possess multiple antigenic epitopes that could be recognized by the acquired immune system. Some C. trachomatis molecules [proteins, lipopolysaccharide (LPS), lipids and CpG-oligonucleotides] have pathogen-associated molecular patterns which can be recognized by innate immune system receptors (PRRs).
Avoiding innate immunity C. trachomatis elementary bodies have evolved to avoid innate immunity in the reproductive tract. Innate immune mechanisms include those triggered by membrane bound host PRRs, such as the Toll-like receptors (TLRs) [29] and NOD-1 [30] which depend on NF-kB signalling. Although C. trachomatis LPS and proteins activate PRRs in vitro, responses to live infection are more muted suggesting that disruption of NF-kB signalling inhibits innate responses [31] . NF-kB was degraded in C. trachomatis-infected human trophoblast cells [32 ] .
Fallopian tubes from C. trachomatis-infected women with ectopic pregnancy have increased inducible nitric oxide synthase (iNOS) and increased pro-inflammatory molecules, activins, which are involved in scarring [33 ] . Thus inflammation may kill bacteria but chronic inflammation can cause tissue damage and this may partly explain why this study, like others, failed to detect C. trachomatis in diseased Fallopian tubes.
Immunological markers of infection, disorder and protective immunity
Antibodies and T-lymphocyte responses to several C. trachomatis proteins have been described. Infection rate and organism load on re-infection decrease with age suggesting development of at least partial protective immunity [34] .
Antibody responses require CD4-T-lymphocyte 'help'. B-lymphocytes and antibodies recognize 'native-protein' epitopes which are not necessarily linear, whereas Tlymphocytes recognize short linear peptides in the con-text of self MHC-I for CD8-T-cells and self MHC-II for CD4-T-cells. CD4-T-cells can be activated as proinflammatory Th17 and Th1 cells or as Th2 cells. Both Th1 and Th2 cells help B-cells to make antibody but the immunoglobulin subclasses produced differ. As different immunoglobulin subclasses vary in biological activity this may be relevant to pathology following infection.
A major antigenic source is the inclusion body. C. trachomatis encodes 50 inclusion body (Inc) proteins, 22 of which are in inclusion membranes [35] . Antibodies to Inc proteins are found in sera from infected women [11 ,35] , and both CD4- [36 ] and CD8- [37] T-cells respond to Inc epitopes. Not all C. trachomatis proteins generate antibodies in every individual. Commercially available tests detect antielementary body antibodies by immunofluorescence or anti-MOMP antibodies by ELISA. Anti-elementary body antibodies were correlated with Fallopian tube damage in subfertile women [38] . ELISA assays suggest that CT795 [39 ] and the plasmid-encoded Pgp3 [40 ] may be good serological markers of infection. Infected women have IgG antibodies to MOMP, IncB and IncC and IgG2 (a Th1 dependent subclass) is the prevalent subclass of anti-Inc antibodies [11 ] . Antibody titres to IncB and IncC correlate with cervicitis and PID, being highest in cervicitis [11 ] .
CD4-T-cell responses to IncB and IncC in infertile women generated a Th2 cytokine pattern whilst fertile women showed a Th1 pattern [8 ] .
C. trachomatis heat shock proteins (cHSPs) are analogous to human HSPs and antibodies to cHSP60 are associated with autoimmunity [41 ] . C. trachomatis STI is associated with antibodies to sperm in semen and IgG antibodies to cHSP60 are associated with reproductive failure. Sperm have several surface HSPs and crossreaction with cHSPs may initiate autoimmune responses to sperm [42 ] . IgG responses to cHSP60 do not correlate with pathology in women [43 ] but women with tubal infertility have a high prevalence of antibodies to cHSP60 [44 ] .
Rank and Whittum-Hudson [45 ] reviewed experimental evidence for protective acquired immunity. In guinea pigs, antibody protects against re-infection and serum IgG is more important than local IgA. In mice both Th1 cells and antibody contribute directly to protection. MOMP is immunodominant, but MOMP immunization only protects if the protein is nonreduced, emphasizing the importance of native-protein B-cell epitopes. Antibiotic therapy clears experimental infection but prevents generation of immunity [45 ] .
Vaccination
Important considerations for vaccination include: who to vaccinate; which antigen(s) to use; which administration route to use; and which adjuvant to use.
There are two stages in the C. trachomatis lifecycle which a prophylactic vaccine should 'hit': cell-adhesion, for which antibody would be most useful, and early-mid replication, where T-cells might be targeted against bacterial antigens in infected cell membranes. Both responses would require CD4-T-cell activation. Acquired immunity is polarized by the antigen presenting cells (usually local dendritic cells) which first activate CD4-Tcell responses. Thus adjuvant activation of dendritic cells local to the vaccination site is crucial. It should be remembered that, although animal studies establish general principles, the fine details of immunity differ between species, and, although C. trachomatis is closely related to the widely used murine pathogen C. muridarum (which is, somewhat confusingly, also referred to as the mouse pneumonitis strain of C. trachomatis), their biology is not identical.
A strong IFN-g response of lymphocytes to C. trachomatis antigen correlates with resistance to infection among sex workers [46 ] . An immunoproteomic analysis of Chlamydia muridarum indicates the two most likely vaccine candidates were PmpG and PmpE/F, which several mouse strains recognize. However, peptides of these proteins used to vaccinate one mouse strain are not recognized by others, arguing for whole protein rather than peptide vaccination. CpG oligonucleotide adjuvant does not induce protection perhaps due to lack of Th17 induction [46 ] . The balance between Th1/Th17 responses explains different susceptibilities of mouse strains to C. muridarum [47 ] . MOMP administered in Lipid-C adjuvant both transcutaneously [48 ] and orally [49 ] induces protection against vaginal C. muridarum, which is enhanced via the oral route when CpG oligonucleotides and cholera toxin are incorporated into the Lipid-C [49 ] . CT043, a conserved Inc protein, is a CD4-T-cell target and may be a vaccine candidate [50 ] . C. trachomatis ArtJ (a protein conserved among chlamydial species) may also be a vaccine candidate with the additional benefit of generating protection against the related human lung pathogen Chlamydia pneumoniae [51 ] . CPAF induces protection against vaginal C. muridarum which is boosted with IL-12 or CpG oligonucleotides as adjuvant [52 ] . Live infection induces Th1 responses whereas immunization with inactivated organisms induces Th2 responses [53 ] . TARP is an immunodominant protein and protects mice against C. muridarum infection [54 ] .
The human C. trachomatis 'antigen-ome' in sera from 99 infected women is very broad as more than 700 C. trachomatis proteins were recognized by more than one serum [55 ] . Mice given either live C. trachomatis infection or immunized with dead organisms were used to identify infection dependent and independent antigens which were tested against sera from infected women. The most recognized infection dependent protein (by 94% of sera) is CPAF. The most recognized infection independent protein (by 96% of sera) is Pgp3 [55 ] . Use of serologically recognized proteins to identify CD4-Tcell epitopes also identified CPAF as a widely recognized serological antigen although in this series CT875 was the most commonly recognized protein [56 ] . MOMP is the most widely recognized T-cell epitope but CT875 stimulates most combined T-cell and serum responses [56 ] .
Conclusion
Understanding the natural history of infection, the host immune response and how these impact on subsequent pathology is crucial to rational vaccine design. Prophylactic vaccination aims to protect before infection. Therapeutic vaccination aims to boost or alter the immune response generated in previously infected individuals.
There can be no doubt that vaccines against C. trachomatis would be of benefit to health and are likely to have a significant impact on healthcare costs. More work on identifying and testing vaccine candidates and appropriate delivery systems is needed.
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